I.v. BU/fludarabine Plus Melphalan or TBI in Unrelated Cord Blood Transplantation for High-Risk Hematological Diseases

Bone Marrow Transplantation - United Kingdom
doi 10.1038/bmt.2014.316
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Excellent Survival Chances After Pharmacokinetic-Targeted Busulfan Plus Fludarabine and ATG for Children With Hurler Syndrome Undergoing Unrelated Cord Blood Transplantation

Biology of Blood and Marrow Transplantation
TransplantationHematology
2018English

Busulfan, Fludarabine, and Alemtuzumab Conditioning and Unrelated Cord Blood Transplantation in Children With Sickle Cell Disease

Biology of Blood and Marrow Transplantation
TransplantationHematology
2013English

Risk Factors and Options to Improve Engraftment in Unrelated Cord Blood Transplantation

Stem Cells International
Cell BiologyMolecular Biology
2011English

Melphalan 140mg/M2 Combined With TBI2(4)Gy and Fludarabine 125mg/M2 as Conditioning for Elderly Patients With Hematological Malignancies in Unrelated Bone Marrow Transplantation Is Comparable in Safety and Effectiveness With TBI/Cy for Younger Patients

Biology of Blood and Marrow Transplantation
TransplantationHematology
2012English

Unrelated Cord Blood Transplantation in CML: Japan Cord Blood Bank Network Analysis

Bone Marrow Transplantation
TransplantationHematology
2008English

Role of HLA Compatibility in Unrelated Cord Blood Transplantation

Major Histocompatibility Complex
2013English

Unrelated Cord Blood Transplantation and Post-Transplant Cyclophosphamide

Haematologica
Hematology
2018English

Optimization of Unrelated Donor Cord Blood Transplantation for Thalassemia: Implications for Other Non‐Malignant Indications Such as HIV Infection or Autoimmune Diseases

2017English

Treatment of Fanconi Anemia Patients Using Fludarabine and Low-Dose TBI, Followed by Unrelated Donor Hematopoietic Cell Transplantation

Bone Marrow Transplantation
TransplantationHematology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy